Business
Mainz Biomed Announces U.S. Extension of ColoFuture Study to Evaluate Integration of Novel mRNA Biomarkers into ColoAlert
eAArly DETECT expected to complete enrollment in Q1 2023 with results in 1H 2023Enhances ColoFuture’s demographic profile and expedites data read-out
About this update from Quantum Cyber N.v.
[{"type":"text","content":"eAArly DETECT expected to complete enrollment in Q1 2023 with results in 1H 2023Enhances ColoFuture’s demographic profile and expedites data read-out timelinePotential to identify advanced adenomas, a type of pre-cancerous polyp often attributed to colorectal cancer (CRC) BERKELEY, Calif. and MAINZ, Germany, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the initiation of eAArly DETECT, its U.S. extension of ColoFuture, the Company’s European feasibility study evaluating the integration of a portfolio of novel gene expression (mRNA) biomarkers into ColoAlert, Mainz’s highly efficacious, and easy-to-use detection test for colorectal cancer (CRC) being commercialized across Europe and in select international territories. ColoFuture/eAArly DETECT are multi-center studies assessing the potential of these biomarkers to identify advanced adenomas, a type of pre-cancerous polyp often attributed to CRC. “We are excited by the opportunity to expand the ColoFuture study to the U.S. as it enables us to accelerate the timeline to evaluate the potential of these biomarkers to be incorporated into our U.S. pivotal study, which is on track to initiate later this year,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “The combinatory U.S. and European studies represent groundbreaking work in the field, as the potential inclusion of advanced adenomas in ColoAlert’s technical profile will represent a transformational advancement in self-administered CRC screening.” Five novel gene expression (mRNA) biomarkers were in-licensed from the Université de Sherbrooke, Quebec, Canada, in early January 2022. In the institution’s pioneering work, researchers tested a battery of novel transcriptional biomarkers using colon cancer samples and precancerous lesions. The five mRNA targets chosen by Mainz Biomed provided the greatest sensitivity and specificity of detection (Herring et al. 2021) and demonstrated a unique ability to identify curable precancerous colonic polyps, as well as treatable early-stage CRC. The eAArly DETECT study will evaluate the effectiveness of these biomarkers to enhance ColoAlert’s product specifications to extend its capability to include the identification of a...